GVHD: pathophysiology and novel agents
GVHD: pathophysiology and novel agents
复制标题
GVHD：病理生理学和新药
DOI：
10.11406/rinketsu.63.1261
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
橋本 大吾
中科院分区：
文献类型：
--
作者：
荒 隆英;橋本 大吾
移植物抗宿主病（GVHD）是异基因造血干细胞移植（allo-SCT）的一种潜在的危及生命的并发症。对GVHD病理生理机制的研究进展促进了新型GVHD治疗药物的开发。在急性GVHD中，新出现的证据表明它靶向皮肤，肝脏和肠道中的组织干细胞，导致治疗无效。此外，抗微生物肽缺乏、肠道微生物群的营养状态改变和抗生素施用导致肠道生态失调，这与allo-SCT后GVHD发作和治疗相关死亡率相关。本文综述了近年来对GVHD病理生理机制的研究进展，并介绍了治疗和预防急性和慢性GVHD的新药物。
Graft-versus-host disease (GVHD) is a potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-SCT). Recent advances in understanding the GVHD pathophysiology promoted development of novel therapeutic agents for GVHD. In acute GVHD, emerging evidence suggested that it targets tissue stem cells in the skin, liver, and gut, resulting in treatment refractoriness. Furthermore, antimicrobial peptide deficiency, nutritional status alteration of the gut microbiota, and antibiotic administration lead to gut dysbiosis, which is related to GVHD onset and treatment-related mortality after allo-SCT. In this review, recent advances in understanding the GVHD pathophysiology are summarized, and novel agents for the treatment and prophylaxis of acute and chronic GVHD are introduced.